98. Eosinophilic gastrointestinal disease Clinical trials / Disease details
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05095116 (ClinicalTrials.gov) | February 10, 2022 | 14/10/2021 | Expanded Access Protocol for Patients With Eosinophilic Esophagitis | APT-1011 (Fluticasone ODT) Expanded Access Protocol for Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: APT-1011 3 mg HS | Ellodi Pharmaceuticals, LP | NULL | Available | 12 Years | N/A | All | United States |